TABLE 3.

Transfusions and Phlebotomy Losses

	Darbe, n = 33	Epo, n = 33	Placebo, n = 33	P1 =	P2 =
Transfusions/subject	1.2 ± 2.4	1.2 ± 1.6	2.4 ± 2.9	.015	.949
	0 [0, 1]	0 [0, 2]	1 [0, 4]
Donors/subject	0.7 ± 1.2	0.8 ± 1.0	1.2 ± 1.3	.044	.558
	0 [0, 1]	0 [0, 2]	1 [0, 2]
Volume, mL/kg	30 ± 58	23 ± 33	51 ± 65	.041	.600
	0 [0, 29.2]	0 [0, 36.6]	20.0 [0, 87.9]
Volume, mL/kg, transfused subjects only	75.6 ± 73.2	48.0 ± 32.7	80.7 ± 65.3	.36	.61
	45 [20.0, 102.4]	39.8 [21.5, 65.7]	83.3 [20.0, 97.8]
Subjects not transfused, n (%)	20 (59%)	17 (52%)	12 (38%)	.088	.620
Transfusion protocol violations/transfused subject, total	0.8 ± 1.7	1.1 ± 1.1	0.9 ± 1.4	.805	.661
	0 [0, 1]	1 [0, 1]	0 [0, 1]
Due to high hematocrit	0.7 ± 1.7	0.8 ± 1.1	0.5 ± 1.3	.435	.895
	0 [0, 1]	0.5 [0, 1]	0 [0, 0]
Due to low transfusion volume	0.2 ± 0.4	0.3 ± 0.8	0.4 ± 0.6	.300	.381
	0 [0, 0]	0 [0, 0]	0 [0, 1]
Total phlebotomy losses, mL/kg	32.3 [20.3–42.5]	29.9 [20.4–42.5]	24.9 [20.4–53.0]	.732	.802
	43.7 ± 45.3	42.5 ± 31.0	55.9 ± 53.9
Pre study	3.6 [1.6–7.2]	5.8 [3.4–8.9]	6.4 [3.7–9.0]	.137	.267
	5.6 ± 6.5	6.1 ± 4.4	7.9 ± 7.5
During study	32.3 [20.3–42.5]	29.9 [20.4–42.5]	24.9 [20.4–53.0]	.974	.801
	37.7 ± 43.1	35.5 ± 30.7	46.9 ± 49.5
Post study	0 [0–0]	0.2 [0–1.3]	0.3 [0–1.0]	.191	.015
	0.5 ± 1.1	0.9 ± 2.0	1.1 ± 2.1

Values represent mean ± SD and median [first quartile, third quartile]. Phlebotomy losses are represented by 95% confidence intervals. P₁, Darbe plus Epo (combined) versus placebo; P₂, Darbe versus Epo